Nasus Pharma Ltd.(NSRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NSRX Nasus Pharma Ltd.

休市中 10-02 16:00:00 EDT

3.92

+0.11

+2.75%

盘后3.93

+0.01+0.26%

19:30 EDT

最高4.10	最低3.79	成交量2.87万
今开3.82	昨收3.82	日振幅8.13%
总市值4,609万	流通市值2,436万	总股本1,176万
成交额11.40万	换手率0.46%	流通股本621.40万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":3.92,"timestamp":1790971200000,"preClose":3.815,"halted":0,"volume":28711,"hourTrading":{"tag":"盘后","latestPrice":3.93,"preClose":3.92,"latestTime":"19:30 EDT","volume":187,"amount":735.84,"timestamp":1790983803507,"change":0.01,"changeRate":0.002551,"amplitude":0.002551},"delay":0,"changeRate":0.02752293577981651,"floatShares":6214000,"shares":11758900,"eps":-1.06915,"marketStatus":"休市中","change":0.105,"latestTime":"10-02 16:00:00 EDT","open":3.82,"high":4.1,"low":3.79,"amount":113956.3018176,"amplitude":0.081258,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.06915,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":3.815,"postHourTrading":{"tag":"盘后","latestPrice":3.93,"preClose":3.92,"latestTime":"19:30 EDT","volume":187,"amount":735.84,"timestamp":1790983803507,"change":0.01,"changeRate":0.002551,"amplitude":0.002551},"volumeRatio":0.5521855848750273},"requestUrl":"/m/hq/s/NSRX","defaultTab":"news","newsList":[{"id":"1140248896","title":"Nasus Pharma宣布FDA批准启动Ns002治疗过敏性休克临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1140248896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140248896?lang=zh_cn&edition=full","pubTime":"2026-09-14 20:01","pubTimestamp":1789387282,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd.（纳斯达克代码：NSRX）今日宣布，美国食品药品监督管理局（FDA）已批准其新药临床试验申请（IND），准许公司启动Ns002用于治疗过敏性休克的临床研究。这一里程碑式的进展，标志着该候选药物正式迈入临床开发阶段，为严重过敏反应患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197206772","title":"纳斯制药任命资深药企高管 Brendan P. O'Grady 为首席执行官，引领战略增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1197206772","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197206772?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:35","pubTimestamp":1785238543,"startTime":"0","endTime":"0","summary":"以色列特拉维夫，2026年7月28日——纳斯制药有限公司是一家专注于创新鼻内产品开发的临床阶段制药公司。今日，该公司宣布任命药界资深人士 Brendan P. O'Grady 为其新任首席执行官。O'Grady 先生将引领公司迈入下一增长阶段，其首要任务是释放 NS002 的商业潜力，推进公司产品管线及业务发展计划，并最大化其专有 Nasax 鼻内给药技术平台的价值。此次领导层交接已于2026年7月27日生效，O'Grady 先生接替 Dan Teleman 的职务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","NSRX","BK4007","BK4232","BK4022","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129096284","title":"纳斯制药任命医药行业资深人士Brendan P. O'Grady为首席执行官，引领战略增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1129096284","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129096284?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:31","pubTimestamp":1785238273,"startTime":"0","endTime":"0","summary":"纳斯制药（Nasus Pharma Ltd.）近日宣布，任命医药行业资深高管Brendan P. O'Grady为公司新任首席执行官。这一关键人事变动，旨在推动企业的战略扩张与未来发展。O'Grady先生将全面负责公司的运营管理，并主导实施其长期增长战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138787740","title":"Nasus Pharma公布鼻内给药昂丹司琼（Ns003）临床前药代动力学与安全性研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1138787740","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138787740?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:00","pubTimestamp":1781006426,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. 近日宣布，其研发的鼻内给药昂丹司琼（Ns003）在临床前药代动力学与安全性研究中取得了积极成果。该研究数据表明，Ns003在实验模型中展现出良好的药代动力学特征与耐受性，为后续的临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nasuspharma.com;ir.nasuspharma.com","stockEarnings":[{"period":"1week","weight":0.1264},{"period":"1month","weight":0.0398},{"period":"3month","weight":0.12},{"period":"6month","weight":0.6681},{"period":"1year","weight":-0.3718},{"period":"ytd","weight":-0.5716}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nasus Pharma Ltd.是一家以色列公司，于2019年5月在以色列注册成立。他们是一家临床阶段的专业制药公司，主要专注于开发治疗紧急医疗状况的鼻内药物。他们正在开发一种独特的PBI技术，拥有专门的产品组合，以应对急性医疗状况和公共健康威胁。","exchange":"AMEX","name":"Nasus Pharma Ltd.","nameEN":"Nasus Pharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nasus Pharma Ltd.(NSRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nasus Pharma Ltd.(NSRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nasus Pharma Ltd.,NSRX,Nasus Pharma Ltd.股票,Nasus Pharma Ltd.股票老虎,Nasus Pharma Ltd.股票老虎国际,Nasus Pharma Ltd.行情,Nasus Pharma Ltd.股票行情,Nasus Pharma Ltd.股价,Nasus Pharma Ltd.股市,Nasus Pharma Ltd.股票价格,Nasus Pharma Ltd.股票交易,Nasus Pharma Ltd.股票购买,Nasus Pharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nasus Pharma Ltd.(NSRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nasus Pharma Ltd.(NSRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}